全文获取类型
收费全文 | 114339篇 |
免费 | 4876篇 |
国内免费 | 1692篇 |
专业分类
耳鼻咽喉 | 1058篇 |
儿科学 | 2313篇 |
妇产科学 | 461篇 |
基础医学 | 6648篇 |
口腔科学 | 902篇 |
临床医学 | 6749篇 |
内科学 | 4070篇 |
皮肤病学 | 186篇 |
神经病学 | 39180篇 |
特种医学 | 5285篇 |
外国民族医学 | 6篇 |
外科学 | 33867篇 |
综合类 | 6596篇 |
现状与发展 | 8篇 |
一般理论 | 6篇 |
预防医学 | 1140篇 |
眼科学 | 692篇 |
药学 | 2739篇 |
63篇 | |
中国医学 | 166篇 |
肿瘤学 | 8772篇 |
出版年
2023年 | 2119篇 |
2022年 | 3397篇 |
2021年 | 4312篇 |
2020年 | 4244篇 |
2019年 | 2258篇 |
2018年 | 2526篇 |
2017年 | 2887篇 |
2016年 | 3226篇 |
2015年 | 4188篇 |
2014年 | 7580篇 |
2013年 | 7023篇 |
2012年 | 7037篇 |
2011年 | 6965篇 |
2010年 | 5956篇 |
2009年 | 5083篇 |
2008年 | 4782篇 |
2007年 | 4841篇 |
2006年 | 4294篇 |
2005年 | 3945篇 |
2004年 | 3770篇 |
2003年 | 3460篇 |
2002年 | 3194篇 |
2001年 | 3041篇 |
2000年 | 2802篇 |
1999年 | 2662篇 |
1998年 | 1351篇 |
1997年 | 1136篇 |
1996年 | 1052篇 |
1995年 | 702篇 |
1994年 | 615篇 |
1993年 | 535篇 |
1992年 | 1496篇 |
1991年 | 1412篇 |
1990年 | 1318篇 |
1989年 | 1128篇 |
1988年 | 949篇 |
1987年 | 601篇 |
1986年 | 242篇 |
1985年 | 336篇 |
1984年 | 292篇 |
1983年 | 204篇 |
1982年 | 298篇 |
1981年 | 222篇 |
1980年 | 181篇 |
1979年 | 167篇 |
1978年 | 174篇 |
1977年 | 120篇 |
1976年 | 104篇 |
1974年 | 89篇 |
1973年 | 97篇 |
排序方式: 共有10000条查询结果,搜索用时 265 毫秒
1.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
2.
3.
4.
5.
Georg Prokop Benedikt Wiestler Daniel Hieber Fynn Withake Karoline Mayer Jens Gempt Claire Delbridge Friederike Schmidt-Graf Nicole Pfarr Bruno Märkl Jürgen Schlegel Friederike Liesche-Starnecker 《International journal of cancer. Journal international du cancer》2023,153(9):1658-1670
Intratumor heterogeneity is a main cause of the dismal prognosis of glioblastoma (GBM). Yet, there remains a lack of a uniform assessment of the degree of heterogeneity. With a multiscale approach, we addressed the hypothesis that intratumor heterogeneity exists on different levels comprising traditional regional analyses, but also innovative methods including computer-assisted analysis of tumor morphology combined with epigenomic data. With this aim, 157 biopsies of 37 patients with therapy-naive IDH-wildtype GBM were analyzed regarding the intratumor variance of protein expression of glial marker GFAP, microglia marker Iba1 and proliferation marker Mib1. Hematoxylin and eosin stained slides were evaluated for tumor vascularization. For the estimation of pixel intensity and nuclear profiling, automated analysis was used. Additionally, DNA methylation profiling was conducted separately for the single biopsies. Scoring systems were established to integrate several parameters into one score for the four examined modalities of heterogeneity (regional, cellular, pixel-level and epigenomic). As a result, we could show that heterogeneity was detected in all four modalities. Furthermore, for the regional, cellular and epigenomic level, we confirmed the results of earlier studies stating that a higher degree of heterogeneity is associated with poorer overall survival. To integrate all modalities into one score, we designed a predictor of longer survival, which showed a highly significant separation regarding the OS. In conclusion, multiscale intratumor heterogeneity exists in glioblastoma and its degree has an impact on overall survival. In future studies, the implementation of a broadly feasible heterogeneity index should be considered. 相似文献
6.
《Journal of the Academy of Nutrition and Dietetics》2022,122(1):225-232
7.
8.
9.
10.
《Neuromuscular disorders : NMD》2022,32(1):25-32
Autoantibodies against 3?hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and the signal recognition particle (SRP) are representative antibodies causing immune-mediated necrotizing myopathies (IMNM), called as anti-HMGCR and anti-SRP myopathies, respectively. Here, we analyzed the differences in routine blood test results between 56 anti-HMGCR and 77 anti-SRP myopathy patients. A higher alanine transaminase (ALT) level and a lower aspartate transaminase (AST)/ALT ratio were observed in anti-HMGCR myopathy patients [ALT, 265.7 ± 213.3 U/L (mean ± standard deviation); AST/ALT ratio, 0.88 ± 0.32] than in anti-SRP-myopathy patients (ALT, 179.3 ± 111.2 U/L, p < 0.05; AST/ALT ratio, 1.28 ± 0.40, p < 0.01). In the active phase, anti-HMGCR myopathy often showed ALT predominance, whereas anti-SRP myopathy often showed AST predominance. In addition, there were differences in erythrocyte sedimentation rate (ESR), total cholesterol (TChol) level, and high-density lipoprotein (HDL) level between anti-HMGCR and anti-SRP myopathies (ESR: HMGCR, 24.4 ± 20.8 mm/1 h; SRP, 35.7 ± 26.7 mm/1 h, p = 0.0334; TChol: HMGCR, 226.7 ± 36.6 mg/dL; SRP, 207.6 ± 40.8 mg/dL, p = 0.0163; HDL: HMGCR, 58.4 ± 13.9 mg/dL; SRP, 46.2 ± 17.3 mg/dL, p < 0.01). Additional studies on the differences in routine blood test results may further reveal the pathomechanisms of IMNM. 相似文献